BMS-754807

Overview

BMS-754807 is under investigation in clinical trial NCT00908024 (Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Assessment of Blood Glucose Changes in Healthy Volunteers After BMS-754807 Alone or BMS-754807 With Metformin	2012/02/03	NCT01525823	Phase 1	Completed	Bristol-Myers Squibb
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors	2010/10/20	NCT01225172	Phase 2	Terminated	Bristol-Myers Squibb
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors	2009/05/25	NCT00908024	Phase 1	Terminated	Bristol-Myers Squibb
Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan	2009/05/12	NCT00898716	Phase 1	Completed	Bristol-Myers Squibb
Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors	2008/11/19	NCT00793897	Phase 1	Completed	Bristol-Myers Squibb
Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer	2008/11/10	NCT00788333	Phase 1	Completed	Bristol-Myers Squibb
Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors	2007/12/06	NCT00569036	Phase 1	Completed	Bristol-Myers Squibb

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

Gastrointestinal Organoids Advance Colorectal Cancer Research Through Enhanced Disease Modeling and Drug Screening

6 months ago

Gastrointestinal organoids have emerged as powerful three-dimensional models that bridge the gap between traditional cell cultures and animal models, offering superior disease modeling capabilities for colorectal cancer research.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access